U.S. Healthcare Services Stock News

Wondering if Alkermes at around US$29.37 is a bargain or already pricing in its prospects? This article walks through how the numbers stack up so you can judge the value for yourself. The stock has returned 8.0% over the last 7 days, while the 30 day return is an 8.8% decline, with year to date performance at 3.9% and a 12.8% decline over the past year. Recent coverage has focused on Alkermes as a listed US pharmaceuticals and biotech name, putting attention on how investors are weighing its...

Epsilon Energy (EPSN) has just posted its FY 2025 numbers with third quarter revenue of about US$9.0 million and basic EPS of US$0.05, set against trailing twelve month revenue of US$45.7 million and EPS of US$0.27 that came alongside 11.2% earnings growth and a trailing net margin of 12.9% compared with 17% a year earlier. Over recent quarters the company has seen revenue move from US$7.3 million in Q2 2024 to US$16.2 million in Q1 2025, then to US$9.0 million in Q3 2025. Quarterly EPS has...

BioStem Technologies (OTCPK:BSEM) appointed Jodi Ungrodt as a new member of its Board of Directors and Chair of the Audit Committee. The company completed the acquisition of BioTissue Holdings Inc.'s surgical and wound assets, including a national sales force. The transaction expands BioStem's commercial reach into hospital settings and broadens its product portfolio. BioStem Technologies, trading at $4.92, sits at an interesting point in its share price history, with a 25.9% return year to...

If you are wondering whether AMETEK at around US$215 per share looks expensive or offers value, it is helpful to separate price action from underlying worth. The stock has seen mixed moves recently, with a 1.2% gain over the last 7 days, a 7.0% decline over 30 days, and returns of 3.0% year to date, 22.5% over the past year, 54.4% over 3 years, and 74.2% over 5 years. These moves come alongside a steady stream of company updates and industry commentary that keep AMETEK on many investors'...

Zhihu (NYSE:ZH) has posted a mixed FY 2025 update, with Q3 revenue at C¥658.9 million and basic EPS of C¥0.58 loss per share, while trailing 12 month figures show revenue of C¥2.97 billion and basic EPS of C¥1.25. Over recent quarters, revenue has shifted from C¥933.8 million in Q2 2024 to C¥859.2 million in Q4 2024, then to C¥716.9 million in Q2 2025 and C¥658.9 million in Q3 2025. Net income moved from a C¥82.7 million loss in Q2 2024 to a C¥72.5 million profit in Q2 2025, before a C¥46.7...

Why Flywire is On Investors’ Radar Today Flywire (FLYW) has been drawing attention after a stretch where its share price showed a mix of gains over the past month and declines across the past 3 months and year to date. Investors are weighing how this recent trading pattern lines up with the company’s fundamentals and global payments footprint. See our latest analysis for Flywire. With the share price at $12.40, Flywire’s recent 16.5% 1 month share price return contrasts with its 14.3% 3 month...

Glass House Brands (OTCPK:GLAS.F) has just posted a mixed FY 2025 picture, with Q3 revenue of US$38.4 million and a basic EPS loss of US$0.19, set against trailing 12 month revenue of US$196.2 million and a basic EPS loss of US$0.23. Over recent quarters, the company has seen revenue range from US$53.0 million in Q4 2024 to US$59.9 million in Q2 2025, while basic EPS has swung between a profit of US$0.10 in Q4 2024 and a loss of US$0.19 in Q3 2025. This keeps the focus firmly on how...

Inspire Medical Systems (NYSE:INSP) has put forward a proposal to amend its Certificate of Incorporation. Shareholders are scheduled to vote on the amendment at the upcoming annual general meeting. The change targets the company’s core governance framework, which may influence how future decisions are approved and overseen. The vote comes at a time when Inspire Medical Systems shares trade around $51.41, with returns showing an 8.8% decline over the past week and 11.8% over the past month...

Wondering if Albemarle at a last close of US$181.39 still offers value, or if the best gains are already in the rearview mirror. The stock has returned 9.4% over the last 7 days, 2.2% over 30 days, 26.0% year to date, and 143.8% over the past year, while the 3 year and 5 year returns sit at negative 15.5% and 31.7% respectively. Those swings in performance set the scene for a closer look at what might be driving sentiment, from changing expectations around Albemarle's end markets to shifting...

Braze (BRZE) just closed out FY 2026 with fourth quarter revenue of US$205.2 million and a basic EPS loss of US$0.29, while the trailing twelve months show revenue of US$738.2 million and a full year basic EPS loss of US$1.22. Over recent periods, the company has seen quarterly revenue move from US$160.4 million in Q4 FY 2025 to US$205.2 million in Q4 FY 2026, with basic EPS losses in those quarters of US$0.17 and US$0.29 respectively. With losses still weighing on margins, the latest numbers...

Velo3D (VELO) has released its latest FY 2025 figures, reporting Q3 revenue of US$13.6 million and a basic EPS loss of US$0.69, alongside net income excluding extra items of a US$11.8 million loss. This keeps the focus firmly on profitability rather than the top line alone. Over recent quarters, the company’s revenue moved from US$8.2 million in Q3 2024 to US$13.6 million in Q3 2025, while basic EPS shifted from a loss of US$37.54 to a loss of US$0.69 as net losses moved from US$23.1 million...

This article examines whether Natera, at around US$197 a share, still aligns with its underlying worth or whether expectations have already been priced in. The stock has delivered a 31.7% return over the last year and a large 3-year return of about 3.5x, even though the year-to-date move is a 13.8% decline and the last 30 days show a 5.7% decline. Recent coverage around Natera has focused on its position in the pharmaceuticals and biotech space, with investors closely watching how its...

Noah Holdings (NYSE:NOAH) has wrapped up FY 2025 with fourth quarter revenue of C¥733.2 million and net income, excluding extra items, of C¥12.8 million, setting the stage for investors to reassess the story at a share price of US$11.33. Over the past few quarters, the company has seen quarterly revenue move from C¥651.9 million in Q4 2024 to C¥614.6 million, C¥629.5 million and C¥632.9 million in the first three quarters of 2025. Over the same period, basic EPS stepped from C¥1.56 in Q4 2024...

If you are wondering whether Hilton Worldwide Holdings at around US$303 per share offers fair value or is pricing in too much optimism, this breakdown will help you frame the stock through several valuation lenses. The share price closed at US$303.16, with returns of 2.9% over 7 days, a 2.8% decline over 30 days, 3.5% year to date, 29.4% over 1 year, 125.0% over 3 years and 154.0% over 5 years. This raises clear questions about what is already reflected in the price. Recent coverage has...

EDAP TMS (NasdaqGM:EDAP) has reported Q3 2025 revenue of €13.9 million, with a basic EPS loss of €0.13 and net income loss of €5.0 million, while the trailing twelve months show revenue of €63.8 million, basic EPS loss of €0.52 and a net income loss of €19.6 million. Over recent quarters, the company has reported revenue of €13.1 million in Q3 2024, €20.3 million in Q4 2024 and €16.0 million in Q2 2025. Quarterly EPS losses have ranged from €0.05 in Q4 2024 to €0.19 in Q1 2025. This...

Waterdrop (NYSE:WDH) has put solid numbers on the table for FY 2025 so far, with third quarter revenue of ¥974.9 million and basic EPS of ¥0.44, alongside trailing 12 month EPS of ¥1.40 supported by net income of ¥506.4 million on revenue of ¥3.25 billion. Over recent quarters the company has seen revenue move from ¥676.2 million in Q2 2024 to ¥753.7 million in Q1 2025 and then to ¥974.9 million in Q3 2025. Basic EPS progressed from ¥0.24 in Q2 2024 to ¥0.30 in Q1 2025 and ¥0.44 in Q3 2025,...

The U.S. FDA has issued a warning letter to ImmunityBio over allegedly false and misleading promotional claims for its bladder cancer drug Anktiva. The letter focuses on how Anktiva has been marketed to healthcare professionals and patients, and requests corrective action from the company. This regulatory action introduces additional marketing and compliance risk for ImmunityBio at a time when its drug portfolio is gaining wider attention. For investors following ImmunityBio, ticker...

Wondering whether Euronet Worldwide at a last close of US$67.11 still reflects its true worth, or if the market is mispricing the stock. The share price has been under pressure, with returns of a 0.8% decline over 7 days, a 4.8% decline over 30 days, a 9.4% decline year to date, and a 38.8% decline over the past year, adding to an already weak 3-year and 5-year picture of 38.5% and 51.5% declines. Recent news coverage has focused on Euronet Worldwide's position within the Diversified...

KB Home Q1 2026: Earnings slip as margins come under pressure KB Home (KBH) opened fiscal 2026 with Q1 revenue of US$1,077.0 million and basic EPS of US$0.53, alongside net income of US$33.4 million as investors weigh how these figures fit into the broader housing cycle. Over recent quarters the company has seen quarterly revenue move from US$1,391.8 million in Q1 2025 to a peak of US$1,999.9 million in Q4 2024 before easing back to US$1,077.0 million in the latest quarter. Quarterly basic...

AECOM (NYSE:ACM) has extended its multi decade partnership with San Diego Unified School District. The company has been selected as prime consultant to support school modernization, safety, security, and sustainability upgrades. The new role covers projects such as new classrooms, safety and security initiatives, and sustainability improvements across the district. AECOM operates at the intersection of infrastructure, buildings, and environmental services, and this new prime consultant role...

Paysign (PAYS) has wrapped up FY 2025 with fourth quarter revenue of about US$22.8 million and basic EPS of US$0.02, set against trailing twelve month revenue of US$82.0 million and EPS of US$0.14 that follows reported earnings growth of 97.9% over the past year. The company has seen revenue move from US$56.5 million on a trailing basis in Q3 2024 to US$82.0 million by Q4 2025, while trailing EPS has shifted from US$0.15 to US$0.14. This sets up a story where investors are weighing 20.3%...

FuboTV Inc. completed a 1-for-12.00048 stock split on March 24, 2026, rebalancing its share count and per-share price structure. This unusually granular split ratio highlights management’s focus on aligning FuboTV’s capital structure with listing requirements and investor accessibility objectives. Next, we’ll examine how this unconventional stock split ratio could influence FuboTV’s investment narrative and appeal to different investor groups. We've uncovered the 12 dividend fortresses...

If you are wondering whether Duolingo's current share price reflects its true worth, the recent performance gives plenty to think about. The stock recently closed at US$97.68, with returns of a 6.4% decline over 7 days, a 13.5% decline over 30 days, a 44.7% decline year to date and a 71.3% decline over the past year, which has changed how some investors may be assessing its risk and potential. Recent coverage has focused on Duolingo's position in consumer services and how sentiment around...

In March 2026, Banc of California announced plans to redeem the entire US$385,000,000 of 3.25% Fixed-to-Floating Rate Subordinated Notes due 2031, while its Board extended the existing stock repurchase program through March 16, 2027 with about US$83,000,000 remaining for future buybacks. Together, the planned note redemption and extended buyback program underscore how management is actively reshaping the balance sheet and capital return mix using its current liquidity and capital...